Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Hans‐Peter Hartung et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatmentSilvia Delgado, Kottil Rammohan, Simon Faissner et al.|Journal of Neurology|2023Cited by 49